论文部分内容阅读
以利福平为对照,研究利福喷丁在结核病联合化疗中的作用。共收纳菌 阳肺结核560例,随机分入以下三组:1、利福喷丁周1次组;Ⅱ、利福喷丁周2次组;Ⅲ、利福平对照组,满疗程511例。从治后第2月及治疗末痰菌阴转率及X线进步来分析,均见利福喷丁具有和利福平同样的高效,副作用不大。初复治病人利福喷丁周1次组满疗程时痰菌阴转率各为99.0％及95.5％,病灶有效率各为99.31％及95.83％,分别与初复治病人利福平每日组比较,疗效相近(P均>0.05),由此说明利福喷丁的长效性能。本研究结果验证利福喷丁是又一强效的新抗结核药物,并兼有其他已用于临床的利福霉素类所缺乏的长效作用。
Rifampicin as a control, study of rifapentine in tuberculosis combined chemotherapy. A total of 560 cases of bacteria positive pulmonary tuberculosis, were randomly divided into the following three groups: 1, rifabine pentectam 1 group; Ⅱ, rifapeizidine week 2 group; Ⅲ, rifampicin control group, full course of 511 cases. From the second month after treatment and treatment of sputum negative conversion rate and X-ray progress to analyze, are seen rifapentine and rifampin with the same high efficiency, little side effects. In the first re-treatment of patients with rifapeizidine weeks when the first course of full sputum sputum negative conversion rate was 99.0% and 95.5%, respectively, the effective rate of lesions were 99.31% and 95.83%, respectively, and initial treatment of patients rifampin Compared with the daily group, the curative effect was similar (all P> 0.05), thus indicating the long-term performance of rifapentine. Our results validate that rifapentine is another potent new anti-TB drug and has the long-lasting effect of other rifamycins that have been used clinically.